Patents Assigned to Medarex
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110040076
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Patent number: 7888484
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 15, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF
    Publication number: 20110027274
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Application
    Filed: July 29, 2010
    Publication date: February 3, 2011
    Applicant: Medarex, Inc.
    Inventors: Heng Cheng, Qiang Cong, Sanjeev Gangwar, Qian Zhang
  • MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LACKING IN FUCOSYL RESIDUES
    Publication number: 20110028696
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 3, 2011
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. CARDARELLI, David B. PASSMORE, Jenny ALBANESE, Lei ZHU
  • Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
    Patent number: 7875278
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: January 25, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
  • Human anti-B7RP1 neutralizing antibodies
    Patent number: 7868140
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: January 11, 2011
    Assignees: Amgen Inc., Medarex Inc.
    Inventors: Gerald Siu, Wenyan Shen, Steven Kiyoshi Yoshinaga, Haichun Huang
  • Transgenic Trasnchromosomal Rodents for Making Human Antibodies
    Publication number: 20110003319
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: September 9, 2010
    Publication date: January 6, 2011
    Applicants: KYOWA HAKKO KIRIN CO., LTD., MEDAREX, INC.
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Human monoclonal antibodies against CD30
    Publication number: 20100322920
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 4, 2008
    Publication date: December 23, 2010
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • Methods and compounds for preparing CC-1065 analogs
    Patent number: 7847105
    Abstract: A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 7, 2010
    Assignee: Medarex, Inc.
    Inventors: Sanjeev Gangwar, Qian Zhang
  • Methods for characterizing glycosylation sites
    Patent number: 7820399
    Abstract: The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for example, the location of the glycopeptide, the heterogeneity of the glycan attached to the glycopeptide, the mass of the glycopeptide, and/or the peptide sequence.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: October 26, 2010
    Assignee: Medarex, Inc.
    Inventors: Zhigang Wu, Mohan Srinivasan
  • Tripeptide prodrug compounds
    Patent number: 7816317
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: October 19, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 7816578
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: October 19, 2010
    Assignees: Kyowa Hakko Kirin Co., Ltd., Medarex, Inc.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Antibodies against Clostridium difficile toxins and uses thereof
    Publication number: 20100233182
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: July 31, 2009
    Publication date: September 16, 2010
    Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.
    Inventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
  • ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF
    Publication number: 20100233181
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: July 31, 2009
    Publication date: September 16, 2010
    Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.
    Inventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
  • Method of treating CD30 positive lymphomas
    Patent number: 7790160
    Abstract: Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and proteasome inhibitors in combination are disclosed.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 7, 2010
    Assignee: Medarex, Inc.
    Inventors: Elke Pogge Von Strandmann, Andreas Engert, Peter Borchmann, Boris Boell
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20100209435
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: February 15, 2010
    Publication date: August 19, 2010
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3
    Publication number: 20100209432
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Application
    Filed: July 17, 2008
    Publication date: August 19, 2010
    Applicant: MEDAREX, INC.
    Inventors: Jonathan Alexander Terrette, Li-sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
  • CD10-activated prodrug compounds
    Patent number: 7771962
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: August 10, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Protein Purification
    Publication number: 20100190210
    Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity ion exchange chromatography process without the use of an in-process tangential flow filtration step.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 29, 2010
    Applicant: Medarex, Inc.
    Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira
  • Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
    Patent number: 7744875
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 29, 2010
    Assignee: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol